Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Industry Watch.
Press releases published on March 13, 2025
Multiple Sclerosis Therapeutics Market Projected To Witness Substantial Growth, 2025-2032: Biogen Inc., Novartis AG
EIN Presswire
·
March 13, 2025
Multiple Sclerosis Therapeutics Market is estimated to be valued at USD 31.39 Bn in 2025 and is expected to reach USD 41.89 Bn by 2032, exhibiting a CAGR of 4%. BURLINGAME, CA, UNITED STATES, March 13, 2025 /EINPresswire.com/ -- Latest Report, titled “ …
Virtual Health Service Market Projected To Witness Substantial Growth 2025-2032:Teladoc Health, Amwell, Doctor on Demand
EIN Presswire
·
March 13, 2025
virtual health service market size is projected to reach US$ 78.84 Bn by 2030 from an estimated US$ 11.11 Bn in 2023, exhibiting a CAGR of 32.3%. BURLINGAME, CA, UNITED STATES, March 13, 2025 /EINPresswire.com/ -- Latest Report, titled “Virtual Health …
NAYA Announces a 1:12 Reverse Stock Split Effective Pre-Market Opening on March 18, 2025
GlobeNewswire
·
March 13, 2025
SARASOTA, Fla. and MIAMI, March 13, 2025 (GLOBE NEWSWIRE) -- NAYA Biosciences, Inc. (“NAYA”) (NASDAQ: NAYA), a life science portfolio company dedicated to bringing breakthrough treatments to patients in oncology, autoimmune diseases, and women’s health, …
Candel Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights
GlobeNewswire
·
March 13, 2025
Recently announced positive data from pivotal randomized, placebo-controlled phase 3 clinical trial of CAN-2409 in intermediate-to-high risk, localized prostate cancer Recently announced positive final data from randomized controlled phase 2a clinical …
HeartSciences Provides Business Update and Reports Third Quarter Fiscal 2025 Financial Results
GlobeNewswire
·
March 13, 2025
Southlake, TX, March 13, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (“AI”)-powered medical technology company focused on transforming ECGs/EKGs to save lives through …
Shuttle Pharma Announces Closing of $5.75 Million Underwritten Offering
GlobeNewswire
·
March 13, 2025
GAITHERSBURG, Md., March 13, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated …
Sutro Biopharma Reports Full Year 2024 Financial Results and Business Highlights
GlobeNewswire
·
March 13, 2025
– Sutro announced a strategic portfolio review resulting in prioritization of wholly-owned next-generation ADC programs; Key management changes announced as part of transition – – Cash, cash equivalents and marketable securities as of December 31, 2024 of …
Cognition Therapeutics to Report Fourth Quarter and Full Year 2024 Results
GlobeNewswire
·
March 13, 2025
PURCHASE, N.Y., March 13, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage company developing product candidates that treat neurodegenerative disorders, (the “Company” or “Cognition”), plans to release financial …
Generation Bio Reports Business Highlights and Fourth Quarter and Full Year 2024 Financial Results
GlobeNewswire
·
March 13, 2025
- Company is applying its T cell-selective lipid nanoparticle to develop siRNA therapeutics for T cell-driven autoimmune diseases - Lead target and indication to be announced MY 2025 - Cash balance of $185.2 million expected to fund operations into 2H …
IN8bio Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights
GlobeNewswire
·
March 13, 2025
Ongoing Phase 1 and Phase 2 clinical programs continue to exhibit long-term durable remissions in hard-to-treat cancers, including glioblastoma (GBM) and 100% of treated Acute Myeloid Leukemia (AML) patients remaining relapse-free Expanded pipeline with …
Sutro Biopharma Announces Strategic Portfolio Review Resulting in the Prioritization of its Next-Generation ADC Pipeline
GlobeNewswire
·
March 13, 2025
– Sutro will rapidly advance next-generation exatecan and dual-payload ADC programs; luveltamab tazevibulin development to be deprioritized as Sutro continues to seek a partner – – Three INDs for wholly-owned programs expected in the next 3 years, …
The Joint Corp. Reports Fourth Quarter and Year-end 2024 Financial Results
GlobeNewswire
·
March 13, 2025
- Grew revenue from continuing operations 10% annually and 14% quarterly compared to the same period in 2023 - - Increased system-wide sales 9% for both the year and Q4 2024 – SCOTTSDALE, Ariz., March 13, 2025 (GLOBE NEWSWIRE) -- The Joint Corp. (NASDAQ: …
Evoke Pharma, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
GlobeNewswire
·
March 13, 2025
Q4 2024 revenue increased 24.6% over Q3 2024; Full-year 2024 revenue grew 97.8% year-over-year Strong growth in key commercial metrics, including prescriber base, fill rates, and patient enrollments Secured $14.3 million net proceeds in financings, …
Allogene Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update
GlobeNewswire
·
March 13, 2025
Momentum Builds Across Programs with Key Data Milestones Expected in 2025 Cemacabtagene Ansegedleucel (Cema-Cel): First-Line (1L) Consolidation in Large B-Cell Lymphoma (LBCL) Ongoing Pivotal Phase 2 ALPHA3 Trial Advancing with Site Activation and Patient …
aTyr Pharma Announces Fourth Quarter and Full Year 2024 Results and Provides Corporate Update
GlobeNewswire
·
March 13, 2025
Topline data from Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis expected in the third quarter of 2025. Fourth positive DSMB review for efzofitimod in Phase 3 EFZO-FIT™ study reinforces its favorable safety profile. Publication in Science …
Senti Bio Appoints Feng Hsiung to Board of Directors
GlobeNewswire
·
March 13, 2025
SOUTH SAN FRANCISCO, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio,” or the “Company”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene …
Lyra Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
GlobeNewswire
·
March 13, 2025
Company continues to focus on upcoming results from ENLIGHTEN 2 pivotal Phase 3 trial in CRS patients, expected in 2Q 2025 In parallel, the Company continues to analyze data and explore opportunities for LYR-210 in CRS patient cohort with nasal polyps …
Enhanced SAP metadata coverage capabilities for Safyr announced by Silwood Technology
EIN Presswire
·
March 13, 2025
Silwood have significantly increased Safyr's metadata coverage for SAP S/4HANA by harvesting metadata for SAP IDOCs, HANA Calculation Views and Internal Tables. ASCOT, BERKSHIRE, UNITED KINGDOM, March 13, 2025 /EINPresswire.com/ -- Silwood Technology …
Nurix Therapeutics Appoints Drug Development Expert Roy D. Baynes, MB.Bch., M.Med., Ph.D., to Its Board of Directors
GlobeNewswire
·
March 13, 2025
SAN FRANCISCO, March 13, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, announced today the …
‘The Star SEO': An Initiative To Meet the Growing Demand for Specialized SEO Services
EIN Presswire
·
March 13, 2025
DALLAS, TX, UNITED STATES, March 13, 2025 /EINPresswire.com/ -- A holistic marketing approach, SEO is the result of thousands of tactile decisions, spanning specialities and web entities. North Rose Technologies, an industry-leading digital marketing …